TAK-700 R-form
(Synonyms:6-[7(R)-羟基-6,7-二氢-5H-吡咯并[1,2-C]咪唑-7-基]-N-甲基-2-萘甲酰胺)
目录号 : KG11936
CAS No. : 752243-39-3
纯度 : 98%
TAK-700 R-form is a highly selective inhibitor of 17, 20-lyase with IC50 value of 38nM .
TAK-700 is a potent and selective inhibitor of the 17, 20-lyase activity of CYP17A1 which is responsible for androgen biosynthesis. Thus, TAK-700 is selected as a candidate for treatment of prostate cancer through reducing the adrenal androgen production. As an inhibitor of CYP17A1, the selectivity of TAK-700 is important to avoid causing the drug–drug interactions or side effects. TAK-700 shows potent inhibitory activity and high selectivity against 17, 20-lyase over other CYPs including 11-hydroxylase and CYP3A4. The IC50 values for 11-hydroxylase and CYP3A4 are above 1μM and above 10μM, respectively. Moreover, in a monkey model, the administration of TAK-700 is found to significantly reduce serum testosterone and DHEA levels .
Other Forms of Rapamycin:
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
KKL 顾客使用本产品发表的 0 篇科研文献
暂无科研文献
分子式 |
C18H17N3O2
|
分子量 |
307.35
|
CAS号 |
752243-39-3
|
中文名称 |
6-[7(R)-羟基-6,7-二氢-5H-吡咯并[1,2-C]咪唑-7-基]-N-甲基-2-萘甲酰胺
|
储存方式 |
Store at -20°C
|